Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer ’s disease mouse model

ConclusionsPDDC is a first-in-class therapeutic candidate that normalizes elevated brain ceramides and nSMase2 activity, leading to the slowing of tau spread in AD mice.
Source: Translational Neurodegeneration - Category: Neurology Source Type: research